Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function.

ABSTRACT:

Background

Lenvatinib is an approved first-line treatment for unresectable hepatocellular carcinoma (uHCC). We evaluated the safety and efficacy of lenvatinib versus sorafenib in patients with uHCC who deteriorated to Child-Pugh class B (CP-B) on treatment.

Methods

We retrospectively evaluated patients from REFLECT who deteriorated to CP-B versus those who remained Child-Pugh class A (CP-A) within 8 weeks after randomization. Best overall response and objective response rate (ORR) per modified Response Evaluation Criteria In Solid Tumors (mRECIST) were assessed from baseline. Progression-free survival (PFS) per mRECIST and overall survival (OS) were assessed beginning at week 8.

Results

Patients with CP-B versus CP-A classification receiving lenva

SUBMITTER: Huynh J 

PROVIDER: S-EPMC9425881 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature